Navigation Links
UAB study shows investigational drug may treat biliary cancers
Date:4/15/2008

BIRMINGHAM, Ala. -- Laboratory studies by University of Alabama at Birmingham (UAB) researchers have shown that the investigational drug triphendiol (NV-196) causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments.

The findings were presented April 13 by Ewan Tytler, Ph.D., assistant professor in the UAB Department of Surgery, Gastrointestinal Section, at the annual meeting of the American Association for Cancer Research (AACR).

Tytler and his colleagues assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Triphendiol induced cell death in all three cell lines and pre-treating the cell lines with triphendiol increased the effectiveness of chemotherapy. Animal model studies showed that triphendiol in combination with chemotherapy inhibited tumor growth more effectively than each drug alone.

In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations, Tytler said. Of course, there is still much work to be done before this could become a treatment protocol for cancer patients but our findings are promising and validate the continued development of triphendiol as a possible pancreatic cancer therapy.

Triphendiol is being developed by Marshall Edwards Inc., as a treatment for late stage pancreatic and gall bladder cancer and recently received orphan drug status by the U.S. Food and Drug Administration. Triphendiol has been licensed by Novogen to Marshall Edwards Inc., who funded Tytlers study.

Tytler said that there is an urgent need for new pancreatic cancer treatments because fewer than 20 percent of patients are candidates for surgery. Current treatment is limited to chemotherapy, which is not always effective, as most tumors are resistant to or become resistant to the commonly used chemotherapy drug for pancreatic tumors, gemcitabine.


'/>"/>

Contact: Jennifer Lollar
jpark@uab.edu
205-934-3888
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Study shows that high-dose, high-frequency interferon produces no additional benefit
2. Study finds media coverage of breast cancer focuses too little on prevention
3. USC study finds evidence of gender-related differences in development of colon cancer
4. New study in JCSM finds that obesity can predict upper airway obstruction amongst children
5. Study shows increase of hip and knee replacements in the US
6. Study shows decline in work disability due to rheumatoid arthritis
7. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
8. Study sheds light on deadly lung disease
9. NovoCure presents results from breast cancer pilot study
10. Mayo-led study finds smoking related to subset of colorectal cancers
11. National hospice study reveals gaps in service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... Mediaplanet today ... for organ transplantation while encouraging readers to sign up as an organ donor for ... organ transplant. , An organ donor can save up to 8 saves through ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated ... new solution for Emergency Departments (ED) has been added to their portfolio. Housed ... examination rooms, and with a simplified pallet of information available to the patient, ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... program through the Pennsylvania Cable Network (PCN) during the summer of 2016. The ... Implementation Grant provided by the United States Department of Health and Human Services ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... ... awarded accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the ... with advanced care and patient safety. Only a few hospitals and facilities have ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology: